Teams

Imagine's Offers

The database may not be exhaustive, please do not hesitate to contact us !
  • Renal hypodysplasia
    Genotype Phenotype
    • Cohorts

      CAKUT (Congenital Anomalies of the Kidney and the Urinary Tract)

    • TNGS / WES / WGS*

      CAKUT gene panel

    • Patient samples

      DNA

    Targets
    Therapeutics
    Clinical trials
    Renal Cystic Dysplasia
    Genotype Phenotype
    • Cohorts

      CAKUT cohort

    • Patient samples

      DNA

    Targets
    Therapeutics
    Clinical trials
  • Hereditary podocytopathies (HP) including Steroid-resistant nephrotic syndrome (SRNS)
    Genotype Phenotype
    • Cohorts

      > 2500 patients (SRNS)

    • TNGS / WES / WGS*

      SRNS gene panel

    • Patient samples

      DNA

    Targets
    • In vitro models

      iPS cells

    • In vivo models

      R140Q podocin (KI mouse model)
      Nphs2Flox/Flox (inducible KO mouse model)

    Therapeutics
    Clinical trials
    Alport Syndrome
    Genotype Phenotype
    • Cohorts

      > 100 families with Alport syndrome

    • TNGS / WES / WGS*

      "RENOME" gene panel

    • Patient samples

      DNA

      Fibroblasts

    Targets
    Therapeutics
    Clinical trials
  • Nephronophthisis (NPH)
    Genotype Phenotype
    • Cohorts

      > 1,500 patients with NPH

    • TNGS / WES / WGS*

      CAKUT gene panel or CILIOME gene panel (for ciliopathies)

    • Patient samples

      DNA

    Targets
    • In vitro models

      Immortalized Urine-derived Renal Epithelial cells

    • In vivo models

      Zebrafish models - ongoing

      Mouse models - ongoing

    • Protocols/Technics

      Single cell analysis from urines 
      Renal organoïdes from iPS cells from patients
      Tridimentional cultures of spheres

    Therapeutics
    Clinical trials
    Polycystic kidney disease
    Genotype Phenotype
    Targets
    Therapeutics
    Clinical trials
  • Cystinosis
    Genotype Phenotype
    • Cohorts

      > 150 families

    • Patient samples

      DNA

    Targets
    • In vitro models

      iPS cells

      Urinary renal epithelial cells (UREC)

      Knock-in HEK293 cells with mutations from patients (CRISPR)

    • In vivo models

      Ctns KO mouse model

    • Specific targets

      CTNS

    Therapeutics
    Clinical trials
    Tubular overload due to glomerular injury
    Genotype Phenotype
    • TNGS / WES / WGS*

      "RENOME" gene panel

    • Patient samples

      DNA

    Targets
    • In vivo models

      Mouse model (please contact us)

    Therapeutics
    Clinical trials
  • Cystinosis
    Genotype Phenotype
    • Cohorts

      > 150 familles 

    • Patient samples

      DNA

    Targets
    • In vitro models

      iPSC

      Urinary renal epithelial cells (UREC)

      Knock-in HEK293 cells with mutations from patients using CRISPR/Cas9

    • In vivo models

      Ctns KO mouse model

    • Specific targets

      CTNS

    Therapeutics
    Clinical trials
    Fabry disease
    Genotype Phenotype
    • Cohorts

      Please contact us

    Targets
    Therapeutics
    Clinical trials
    Cystinuria
    Genotype Phenotype
    • Cohorts

      Please contact us

    Targets
    Therapeutics
    Clinical trials
    Proteinuric kidney disease
    Genotype Phenotype
    • Cohorts

      Cohort (please contact us)

    Targets
    Therapeutics
    Clinical trials
  • Chronic Tubulo-Interstitial Nephropathies
    Genotype Phenotype
    • Cohorts

      Please contact us

    Targets
    Therapeutics
    Clinical trials

Contacts

  • Marion Pilorge

    Marion Pilorge

    Business development manager

    • marion.pilorge@institutimagine.org
    • +33 1 42 75 45 65

Our founding members

Our campuses

Our labels